1. Background {#sec1}
=============

Work disability is a major burden of rheumatic conditions \[[@B1], [@B2]\], and a substantial amount of rheumatoid arthritis- (RA-) associated work disability occurs early in the course of the disease \[[@B3]\]. As a result of novel therapeutic concepts, RA-induced work disability rates appear to have decreased \[[@B4], [@B5]\]; nevertheless, the risk of work disability and unemployment is still high in RA patients \[[@B5], [@B6]\], with disability rates of 20% to 30% in the first 2 to 3 years of the disease \[[@B7]\]. Return to work following sick leave or unemployment remains a challenge \[[@B5], [@B6], [@B8]\]; thus, prevention of work disability is of great importance. Even greater than treatment costs are work disability and unemployment, which pose an economic burden to both patients and society \[[@B6]\], making work ability and employment crucial outcomes in RA.

Work ability in RA appears to be multifactorial. A number of sociodemographic and work-related factors, such as age or type of work, have been found to be associated with work disability or unemployment in both cross-sectional and longitudinal studies \[[@B9]\]. Moreover, disease-related variables, including symptoms such as pain, swelling, joint stiffness \[[@B10]\], and functional disability \[[@B11]\] appear to play a major role.

Impaired lower extremity function and hand grip strength affect the quality of life of RA patients, and muscle strength is an indicator of functional disability \[[@B12]--[@B14]\]. Body composition, particularly a reduced amount of lean mass in the arms and legs, is associated with disability in RA patients, and weakness in RA as a result of disuse, muscle atrophy, and increased muscle mass loss is well-known \[[@B15], [@B16]\]. This condition is referred to as rheumatoid cachexia and has been reported in two-thirds of all RA patients \[[@B17], [@B18]\]. Particularly the knee extensor plays an important role in mastering activities of daily living \[[@B14]\] and isotonic and isometric hand exercises in RA patients can decrease pain and disease activity and increase muscle strength and function, in addition to quality of life \[[@B12]\].

A number of studies have identified poor physical function, with or without pain, as a significant determinant of work disability in RA \[[@B19], [@B20]\]. In healthy individuals, only a weak association could be found between muscle strength and work ability \[[@B21]\]; however, to the best of our knowledge, little is known regarding the association between muscle strength, lower extremity function, and work ability in RA patients.

The purpose of the present study was to assess employment status and work ability in patients of working age with RA and to explore the association between muscle strength, lower extremity function, and employment status and work ability, when controlled for relevant sociodemographic and disease-related factors.

2. Methods {#sec2}
==========

This monocentric cross-sectional study was performed at the rheumatology outpatient clinic of the SMZ Süd Hospital (Vienna, Austria), from November 2015 to August 2016 \[[@B22]\]. This study was approved by the Medical Ethical Committee of the Gemeinde-Wien (EK 15-173-0915) and complied with the Declaration of Helsinki. All patients gave informed consent. Anonymity and confidentiality were guaranteed at all times. This study was registered at ClinicalTrials.gov ([NCT02581852](https://clinicaltrials.gov/ct2/show/NCT02581852)).

2.1. Study Sample {#sec2.1}
-----------------

Participants were recruited at the rheumatology outpatient clinic while waiting for their appointment. They were considered eligible if they matched the following inclusion criteria: were of working age (≥18 and ≤65 years); had RA according to the 2010 European League Against Rheumatism (EULAR) classification for seropositive RA \[[@B23]\]; had sufficient knowledge of German, English, Serbo-Croatian, or Turkish to fill in the questionnaire. Patients matching the following criteria were excluded: refused to sign the informed consent; had severe comorbidities (cancer, severe cardiovascular illness, and mental illness).

2.2. Measures {#sec2.2}
-------------

*Employment status*was assessed by asking patients about their current employment situation. Patients were considered gainfully employed if they were in paid work at the time of study inclusion.

*Work ability*was measured using the Work Ability Index-Single Item Scale (WAS), which is the first item of the Work Ability Index (WAI). On a response scale of 0-10, where 0 represents 'unable to work\' and 10 represents 'work ability at its best\', patients reported their current estimate of work ability compared to lifetime best. The complete WAI could only be assessed for employed patients, since most items of the self-evaluation have reference to the current work setting and include the individual\'s current job demand (predominantly physical, mental or mixed). The WAI is commonly used to assess work ability with an adequate test-retest reliability \[[@B24], [@B25]\]. Previous research has demonstrated a high correlation between the WAI and WAS and has established the WAS as a reliable measure for assessing the status and progress of work ability \[[@B26], [@B27]\]. As proposed by Gould et al. \[[@B28]\], classification of the WAS is according to the WAI as follows: poor (0-5 points), moderate (6-7 points), good (8-9 points), and excellent (10 points) work ability.

2.3. Independent Variables and Covariates {#sec2.3}
-----------------------------------------

*Sociodemographic and disease-related factors/characteristics* were assessed by clinical examination and an interview-based questionnaire. Sociodemographic characteristics were gender, age, marital status, and highest level of education. Disease-related characteristics included disease duration, current use of medication for RA and other medical conditions, and comorbidities. For assessing current medication and comorbidities, we used chart review. RA medication was categorized into synthetic disease modifying drugs (sDMARDs), biological disease modifying drugs (bDMARDs), glucocorticoids, and nonsteroidal antirheumatic drugs (NSAIDs)/other pain killers. Comorbidities were summed up to a total number of conditions.

Pain intensity was assessed via a visual analogue scale (VAS) \[[@B29]\]. Disease activity was measured using the Clinical Disease Activity Index (CDAI), a validated and widely used index \[[@B30]\] that includes the assessment of tender joints, swollen joints and overall disease activity and scores from 0-76 points. Laboratory assessments included C-reactive protein (CRP; mg/dl), tumour necrosis factor-alpha (TNF-*α*; pg/ml), and interleukin-6 (IL-6; pg/ml) to assess the current inflammatory profile of the patients. Blood samples were taken in the morning between 8 am and 11 am.

The functional status of activities of daily living was assessed by the German version of the Health Assessment Questionnaire Disability Index (HAQ-DI), which included 20 questions within 8 categories: dressing, rising, eating, walking, grooming, reaching, gripping, and performing errands. The overall disability index is a value between 0 (no functional disability) and 3 (severe functional disability), representing an average score across the domains \[[@B31]\].

*Lower extremity muscle strength*was assessed by measuring knee extensor strength and lower extremity function. Knee extensor strength was evaluated using an isometric dynamometer that measures the maximum strength of the knee extensor in a standardised procedure \[[@B32]\]. During the test, patients were seated upright with 90° flexion in the hips. A load cell (Chatillon, Ametek Inc®) was mounted on the ankle via a length-adjustable cord. Patients were instructed to perform one maximal voluntary contraction, and strength was assessed three times for each leg, with a two-minute break between measurements. The highest value for each leg, presented in kilogram strength (kg), was taken for statistical analyses. Lower extremity function was assessed using the short physical performance battery (SPPB), a group of measures including tests for gait speed, chair stand, and balance, with a five-level categorical score. The summary score ranges from 0 (worst performance) to 12 (best performance) \[[@B33], [@B34]\].

*Hand grip strength*was measured using a portable hydraulic hand dynamometer (Sammons Preston, Rolyan, Bolingbrook, IL, USA). Patients were examined in a standardised position, seated upright with their upper arm adducted, and the elbow flexed at 90° \[[@B35]\]. Three measurements with maximum voluntary strength were taken for each hand, in an alternate order, with a two-minute break between each measurement. The maximum value for each hand was taken for statistical analyses.

2.4. Statistics {#sec2.4}
---------------

Differences between gainfully employed patients and those without employment were tested using a*t*-test, Mann-Whitney U-test, Chi-squared test, or Fisher\'s exact test, as appropriate for the data distribution, type of variable, and group size. Univariate linear regression was used to detect associations between muscle strength, lower extremity function, sociodemographic, disease-related, functional variables, and the outcome parameters. Variables that retained association with employment status and work ability in univariate analysis at a level*p*≤0.2 were included in multivariate analyses. Binary logistic regression was then applied to test the odds between hand grip strength, knee extensor strength, lower extremity function (SPPB), and employment status. Multivariate linear regression was applied to assess the effects of hand grip strength, knee extensor strength, and lower extremity function (SPPB) on work ability. A crude model (model I) was stepwise-adjusted for sociodemographic (model II) and disease-related (model III) parameters. For binary logistic regression, exp(*β*) values with a 95% confidence interval were calculated for all included variables, for each step in the respective models, in addition to Nagelkerke\'s R^2^ as a measure of model fit. For multivariate linear regression, standardised *β*- and*p*-values for all variables, for each step in the model, and explained variance (R^2^) were calculated.

Although gender was not significant in univariate analysis, it remained in the model, since muscle strength is highly dependent on gender \[[@B36]\]. HAQ was not included in the multivariate analysis, due to its mutual relationship with strength and the outcome variables. Disease activity and therapy with NSAIDs/painkillers were not included, due to their multicollinearity with pain intensity. All statistical computations were performed with SPSS version 22.0.2 (IBM Corp, Armonk, NY, USA).

3. Results {#sec3}
==========

One hundred and forty patients with seropositive RA visiting the rheumatology outpatient clinic were consecutively screened for eligibility, with a total of 100 patients being included in the present study. To avoid selection bias, we included all eligible patients of working age, with or without current employment. For those with gainful employment at the time of inclusion, the full score of the WAI was calculated, and for those not gainfully employed, only the WAS was assessed. The WAI and WAS showed a high correlation (Spearman correlation coefficient*r*=0.798,*p*≤0.001), indicating good convergent validity between the two measurement instruments. Muscle strength measurements had a high test-retest reliability. The average measure intraclass correlation coefficients with a 95% confidence interval (CI) for right and left knee extensor strength and right and left hand grip strength were 0.97 (0.96; 0.99), 0.99 (0.98; 0.99), 0.99 (0.98; 0.99), and 0.99 (0.98; 0.99), respectively.

3.1. Descriptive Characteristics of the Total Population and Stratification by Employment Status {#sec3.1}
------------------------------------------------------------------------------------------------

[Table 1](#tab1){ref-type="table"} shows the sociodemographic, professional, and disease-specific characteristics for the total population and stratification by employment status. The mean age of the patients was 50.5 years old (SD 9.7), and two-thirds were female. Most patients were cohabiting and had at least a secondary school education. In addition, most patients filled in the German version of the questionnaires. The mean disease duration was 9 years, the mean disease activity was low (CDAI=8 points), and the mean pain intensity was 3.6 points on a VAS scale of 1-10 points. Most patients reported no disability and were treated with sDMARDs, and almost half were treated with bDMARDs. More than half suffered from at least one comorbidity and took at least one additional medication. The full WAI and the type of work function could only be assessed for those patients who were employed at the time of study inclusion. The average reported work ability, as measured by the WAI and WAS, was moderate (36.5 and 6.2), with 38% poor, 17% moderate, 36% good, and 9% excellent work ability. Most employed patients had a mixed (physical and mental) type of work and reported a good work ability, as measured by the WAI (37.3 points) and WAS (8 points). The median lower extremity function (SPPB) was good (10.9 points), and the mean grip strength and knee extensor strength were 29.4 kg and 36.4 kg, respectively.

The 41% of patients that were not gainfully employed were significantly older, had a lower level of education, and were more likely to have comorbidities and to take additional medication. Of those without employment, CRP and disability levels were higher. Gainfully employed patients reported a good work ability (8 points) as compared with those without employment, who reported poor work ability (4 points) by means of WAS. Gainfully employed patients had better hand grip and knee extensor strength on both sides. Moreover, lower extremity function was better, as measured by the full score of SPPB and the two subcategories, the chair stands and walking test.

3.2. Associations between Muscle Strength, Lower Extremity Function and Employment Status and Work Ability {#sec3.2}
----------------------------------------------------------------------------------------------------------

Tables [2](#tab2){ref-type="table"} and [4](#tab4){ref-type="table"} show the results of the multivariate regression analyses, with employment status and work ability as dependent variables. The independent variables were those found to be relevant in the univariate analysis (*p*≤0.2), as presented in Tables [1](#tab1){ref-type="table"} and [3](#tab3){ref-type="table"}. In the full adjusted model, patients with better knee extensor strength and physical performance, as well as younger patients, had a significantly better chance of gainful employment. The odds for hand grip strength remained significant when adjusted for sociodemographic, but not for clinical, variables. Better hand grip strength and knee extensor strength together with female gender and lower pain, as well as better lower extremity function (SPPB) together with pain, remained significantly associated with work ability after adjusting for sociodemographic and disease-specific variables.

4. Discussion {#sec4}
=============

In the present study, we found an association between employment status, work ability, and parameters of physical fitness. These findings were independent of clinical and socioeconomic parameters.

Despite an improvement in therapeutic management, work disability rates among the RA population are still substantial \[[@B9]\]. There is a broad range of studies regarding work disability and unemployment; however, it must be considered that these outcomes were assessed in different ways and definitions vary among studies, causing difficultly in accurately comparing study results. In the present study,*not being gainfully employed* is defined as not having a paid job at time of study inclusion, whether associated with RA or not; however, in a previous study, unemployment was equated with work disability \[[@B37]\]. In our RA outpatient population, we found that 41% were not gainfully employed and that employment status was not related to disease duration. Looking closer, 56% of the nongainfully employed patients, almost one-quarter of the total study population, had retired early, corresponding to the fraction of work disabled patients in our study.

In a recently published large cohort study, the risk of unemployment was similar in both RA patients and the general population. However, the chance of returning to work following unemployment was significantly lower in the first year after an RA diagnosis and in the subsequent years \[[@B8]\]. Thus, prevention of unemployment appears to be of particular importance in the management of RA patients.

Compared with studies describing good work ability in the healthy population \[[@B26]\], self-reported work ability in our RA population, as measured by the WAS, was moderate (6.2 points), with more than half reporting a poor to moderate work ability. The average WAI in RA patients differs between studies, most likely due to differences in study population characteristics \[[@B38], [@B39]\]. Here, we show that work ability was significantly higher in the gainfully employed as opposed to unemployed patients. Similar results were observed in an intervention study in Denmark \[[@B39]\], although the WAS levels were slightly lower. In the present study, the WAS scores of gainfully employed RA patients were in accordance with workers who remain in employment despite chronic nonspecific musculoskeletal pain \[[@B25]\].

The major contribution of our study to the field is the observed relationship between grip strength, knee extensor strength, lower extremity function, and work ability and employment status. The association of knee extensor strength and lower extremity function remained significant after adjusting for sociodemographic and disease-related parameters.

In our RA population, hand grip strength \[[@B40], [@B41]\] and knee extensor strength \[[@B42]\] were markedly lower than the normative values in the general population. A recent study on frailty and physical function in RA patients \[[@B43]\] revealed a lower than average hand grip strength and a similar level of knee extensor strength; however, the study population was slightly older, but the percentage of women was similar. Another study \[[@B44]\] reported similar values for hand grip strength and knee extensor strength in RA patients in remission. Interestingly, this study also showed that, despite improvement in disease control, the relative loss of muscle mass and increased adiposity in RA patients remained, when matched with healthy controls.

Muscle strength as a potential contributor to work ability in RA is amenable to intervention and can therefore be improved. A 2009 Cochrane review \[[@B45]\] suggests that exercise can improve general muscular endurance and strength without detrimental effects on disease activity or pain in RA. Moreover, progressive resistance training with adequate volume appears to be an effective and safe intervention for stimulating muscle growth and reversing cachexia in RA patients \[[@B16]\]. Furthermore, undertaking a specialised exercise program for the hand has been shown to improve hand function, including grip strength \[[@B46], [@B47]\].

Muscle density has been shown to be strongly associated with disability and lower physical performance in individuals with RA \[[@B48]\]. In our RA population, the average SPPB score was 10.8, and the score of nongainfully employed patients was even lower. This is worrying, since in the older population, limited physical performance of the lower extremities, as measured by an SPPB score lower than 10 points, is predictive of all-cause mortality \[[@B49]\]. Moreover, cognitive function, which is considered a key contributor to work ability \[[@B50]\], was worse in RA patients with a lower SPPB score \[[@B51]\].

In univariate analysis, younger patients with a higher level of education, less pain, lower levels of CRP, the absence of comorbidities, and comedication, and as expected, a higher self-reported work ability, were more likely to be gainfully employed. In multivariate analysis, a younger age remained significantly correlated with a better chance of employment in all models. Better work ability was associated with a younger age, a higher education, longer disease duration, higher disease activity, and more pain. Moreover, female gender and lower pain levels remained independently associated parameters. Functional disability (HAQ-DI) was not included in the multivariate regression but was significantly associated with employment status and work ability in the univariate analysis.

In accordance with our results, a 2006 review summarizing the results of cross-sectional and cohort studies \[[@B52]\] reported that an older age, a lower education level, a higher disability score (HAQ), higher pain levels, and longer disease duration were predictors of work disability. In contrast to our findings, where female gender was associated with better work ability and a higher chance of employment, certain studies have reported that female gender is a risk factor for work disability. It is important to note that, in some studies, it was not specified whether unemployment was related to RA, and different methods were used to assess work disability.

The greatest strength of our study is that it is the first assessment of muscle strength and lower extremity function as potential contributors to work ability and employment status, which greatly contributes to research on work ability among RA patients. Another strength is that we looked at both employment status and work ability; thus, these different concepts can be discussed in parallel. We used standardised objective assessments to quantify grip strength, knee extensor strength, and lower extremity function, and our population represents the typical gender distribution in RA.

There are also some limitations to the present study. The cross-sectional design and relatively small sample size allow us to draw a conclusion from our data about associations, but not about causality. Moreover, the lack of a control group of individuals without RA is a potential limitation. However, literature-reported normative values for the main outcomes and strength parameters are available, and the present study can be considered an approach for generating hypotheses for further interventional approaches or longitudinal studies. Another possible limitation of our methodology is that the population used to create and establish the SPPB value were older adults \[[@B34]\], and the use of this tool is focused on the geriatric population. Nevertheless, since the implementation of SPPB, it has been used in different populations and illnesses in the community dwelling setting \[[@B49]\], including RA \[[@B48], [@B51]\]. The WAS inquiry 'current work ability compared to lifetime best\' may have led to an underestimation of work ability in older patients, since the disease onset could have been at an older age than that in the younger patients. It is possible that the pain-related noncompliance of patients during physical measurements led to a certain degree of bias in the results; however, multivariate analyses were adjusted for pain levels on the day of the physical tests.

5. Conclusions {#sec5}
==============

Work disability occurs early in RA \[[@B3]\]; thus, the WAS should be considered more frequently as an easily applicable outcome measure, since staying at work in spite of this chronic disease must be an important therapeutic goal for physicians and healthcare coverage. We have identified potentially modifiable factors to improve work ability in RA patients. Although interventional studies with specialised rehabilitation programs are needed, our results indicate that work ability and employment may be promoted by improving pain levels, extremity function, and grip and knee extensor muscle strength. According to current guidelines for the management of RA \[[@B53]\], all individuals with RA should be offered access to physiotherapists and occupational therapists. Since prevention of work disability and enhancement of work ability may be more effective than returning to work following unemployment, it seems useful to include functional muscular training, with a focus on strengthening lower extremities in the treatment of RA patients.
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###### 

Characteristics of the study population and univariate comparison of subjects with and without gainful employment.

                                            **Total population(n=100)**   **Gainfully employed subjects(n=59)**   **Non-gainfully employed subject (n=41)**   ***p*-value**                                                                
  ----------------------------------------- ----------------------------- --------------------------------------- ------------------------------------------- --------------- -------------------- ------ ---- -------------------- ------ -------------
  Female gender                             66                                                                    66                                          38                                   64     28                        68.3   0.830
  Age -- years                                                            53.0 \[45.0-57.0\]                                                                                  49.0 \[40.0-54.0\]               58.0 \[51.5-61.0\]          **\<0.001**
  In a relationship                         71                                                                    71                                          44                                   75     27                        66     0.340
  Education level                                                                                                                                                                                                                          **0.013**
   Compulsory                               18                                                                    18                                          5                                    8      13                        34      
   Secondary                                71                                                                    71                                          46                                   78     25                        61      
   Higher                                   11                                                                    11                                          8                                    14     3                         7       
  Disease duration -- months                                              78.00 \[36.5-192\]                                                                                  60.0 \[31-120\]                  78.0 (36.5-192)             0.260
  Disease activity -- CDAI                                                8.0 (8.2)                                                                                           0.8 (7.9)                        8.4 (8.8)                   0.644
  Pain - VAS                                                              3.5 (2.05)                                                                                          3.3 (1.9)                        4.1 (2.2)                   **0.056**
  Inflammatory marker                                                                                                                                                                                                                       
   CRP - mg/dl                                                            3.2 \[1.1-6.7\]                                                                                     2.6 \[0.7-5.0\]                  3.9 \[1.7-8.4\]             **0.035**
   IL-6 - pg/ml                                                           3.9 \[1.98-7.91\]                                                                                   3.7 \[1.7-7.9\]                  4.1 \[2.2-8.2\]             0.443
   TNF-alpha - *µ*g/ml                                                    1.6 \[0.56-2.35\]                                                                                   1.3 \[0.5-2.4\]                  1.9 \[1.1-2.3\]             0.273
  Rheumatoid arthritis medication                                                                                                                                                                                                           
   sDMARDs                                  80                                                                    80                                          46                                   78     34                        83     0.617
   bDMARDs                                  44                                                                    44                                          30                                   50.8   14                        34.1   **0.107**
   Corticosteroids                          17                                                                    17                                          10                                   16.9   7                         17     1.000
   NSAIDs/Pain killers                      15                                                                    15                                          9                                    15.3   6                         14.6   1.000
  Comedication (non-RA)                     55                                                                    55                                          25                                   42.4   30                        73.2   **0.001**
  Number of comedication                                                  1 \[0-3\]                                                                                           0 \[0-2\]                        2 \[0-4\]                   **0.002**
  Comorbidities                                                                                                                                                                                                                             
   Presence of comorbidity                  65                                                                    65                                          32                                   54     33                        81     **0.007**
   Number of comorbidities                                                1 \[0-2\]                                                                                           1 \[0-1\]                        2.0 \[1-3\]                 **0.005**
  Functional Disability (HAQ - DI)                                        0.5 \[0.0-1.0\]                                                                                     0.4 \[0.0-1.0\]                  0.8 \[0.1-1.3\]             **0.009**
   HAQ-DI ≤ 1, no disability                70                                                                    70                                          50                                          27                               **0.067**
   HAQ-DI \>1, disability                   28                                                                    28                                          9                                           12                                
  Job demands *∗*                                                                                                                                                                                                                           
   Predominantly physical                   10                                                                    17                                                                                                                        
   Predominantly mental                     21                                                                    36                                                                                                                        
   Mixed physical and mental                28                                                                    47                                                                                                                        
  Workability index single item (WAS)                                     7.00 \[4.00-7.00\]                                                                                  8.0 \[6.0-9.0\]                  4 \[2.5-7.0\]               **\<0.001**
  Workability index (WAI)*∗*                                              37.3 \[32.4-42.0\]                                                                                                                                                
  Muscle strength - kg                                                                                                                                                                                                                      
   Hand grip strength                                                     29.4 (14.4)                                                                                         32.1(14.9)                       25.5 (12.9)                 **0.024**
   Knee extensor strength                                                 36.4 (16.8)                                                                                         41.5(17.1)                       29.2 (13.6)                 **\<0.001**
  Lower extremity function - (SPPB) total                                 10.8 (1.9)                                                                                          11.3 (1.5)                       10.1 (2.2)                  **0.003**
   Chair stands                                                           3.2 (1.2)                                                                                           3.6 (0.9)                        2.7 (1.3)                   **0.010**
   Balance test                                                           3.7 (0.7)                                                                                           3.8 (0.6)                        3.6 (0.9)                   0.262
   Walking test                                                           3.9 (0.5)                                                                                           3.9 (0.3)                        3.8 (0.7)                   **0.030**

SD=standard deviation, IQR=interquartile range, CDAI=clinical disease activity index, VAS=visual analogue scale, CRP=C-reactive protein, IL-6=interleukin-6, TNF-alpha=tumor necrosis factor-alpha, s/b DMARD=synthetic/biological disease-modifying antirheumatic drug, WAI=workability index, WAS=single item workability index, SPPB=short physical performance battery, and HAQ-DI=health assessment questionnaire-disability index.

*∗* Assessed for gainfully employed patients only.

###### 

Associations between grip strength, knee extensor strength, lower extremity function, and employment status (dependent variable: gainfully employed).

                                Employment status (gainfully employed)                                                                                                
  ----------------------------- ---------------------------------------- --------- ------------ ----------- --------- ------------ ----------- --------- ------------ -----------
  I                             HGS/KES/SPPB^a^                          0.09      1.04*∗*      1.01-1.07   0.22      1.06*∗∗*     1.03-1.10   0.14      1.49*∗*      1.14-1.94
  II^b^                         HGS/KES/SPPB^a^                          0.38      1.05*∗*      1.00-1.09   0.44      1.06*∗*      1.02-1.11   0.41      1.46*∗*      1.07-2.00
                                Age - years                                        0.88*∗∗*     0.83-0.95             0.89*∗∗*     0.83-0.96             0.89*∗∗*     0.83-0.95
  Gender: male                                                           \-        Reference                - -       Reference                - -       Reference    
   female                                                                1.15      0.32-4.16                1.53      0.34-3.96                0.41      0.14-1.23    
  Education: compulsory                                                  - -       Reference                - -       Reference                - -       Reference    
   secondary                                                             4.12*∗*   1.08-15.71               3.88*∗*   1.01-14.88               4.81*∗*   1.25-18.55   
   higher                                                                3.52      0.49-25.93               3.91      0.48-31.66               2.87      0.37-21.87   
  III^c^                        HGS/KES/SPPB^a^                          0.38      1.05         0.99-1.12   0.48      1.07*∗*      1.02-1.13   0.48      1.71*∗*      1.18-2.49
                                Age - years                                        0.89*∗*      0.83-0.96             0.90*∗*      0.83-0.98             0.89*∗*      0.82-0.96
  Gender: male                                                           - -       Reference                \-        Reference                - -       Reference    
   female                                                                1.26      0.30-5.32                1.09      0.29-4.04                0.29      0.08-1.00    
  Education: compulsory                                                  - -       Reference                - -       Reference                - -       Reference    
   secondary                                                             4.32      1.00-18.57               4.09      0.97-17.26               6.59*∗*   1.42-30.64   
   higher                                                                4.81      0.48-47.70               6.05      0.54-68.54               4.97      0.46-53.36   
  bDMARD therapy - yes vs. no                                            2.46      0.85-7.13                2.32      0.78-6.94                2.65      0.88-7.98    
  Comedication - yes vs. no                                              0.67      0.11-3.94                0.48      0.08-2.85                0.66      0.11-3.93    
  Comorbidity - yes vs. no                                               0.93      0.15-5.92                1.46      0.21-10.00               0.93      0.14-6.11    
  Pain intensity - yes vs. no                                            0.92      0.69-1.21                1.00      0.75-1.36                0.96      0.71-1.30    
  CRP - mg /dl                                                           1.02      0.98-1.06                1.02      0.99-1.06                1.04      1.00-1.08    

Binary logistic regression analysis. OR=odds ratios, HGS=handgrip strength, KES=knee extensor strength, SPPB=short physical performance battery, bDMARDs=biological disease modifying antirheumatic drug, and CRP=C-reactive protein.

*∗p*≤ 0.05; *∗∗p*≤ 0.01; ^a^per kg HGS/KES; per point of the SPPB score; ^b^model II adjusted for sociodemographic variables *p*≤0.02 in univariate analysis; ^c^model adjusted for sociodemographic and clinical variables *p*≤ 0.2 in univariate analysis.

###### 

Univariate analysis of associations between sociodemographic, clinical characteristics, and workability (workability index single item, WAS).

  Workability (WAS)                                       
  ------------------------------------------ ----------- -------------
  Age - years                                \- 0.10     **\<0.001**
  Sex: male                                  Reference    
   female                                    0.94        **0.108**
  Marital status: in a relationship          Reference    
   living alone                              -0.19       0.757
  Education: compulsory                      Reference    
   secondary                                 1.26        **0.083**
   higher                                    2.94        **0.005**
  Disease duration - months                  -0.01       **0.003**
  Disease activity (CDAI) - points           -0.10       **0.003**
  Pain (VAS) - points                        -0.67       **\<0.001**
  Functional disability (HAQ) - points       -2.63       **\<0.001**
  CRP - mg/dl                                -0.02       0.275
  IL-6 - pg/dl                               -0.03       0.291
  TNF-alpha - *µ*g/dl                        -0.14       0.217
  RA therapy: sDMARDs                        1.09        **0.111**
   bDMARDs                                   \- 1.52     0.787
   Corticosteroids                           0.32        0.660
   NSAIDs/Pain killers                       \- 1.02     **0.185**
  Comedication                               -1.81       **0.001**
  Comorbidity                                -1.50       **0.009**
  Muscle strength: hand grip - kg            0.05        **0.012**
   Knee extensor - kg                        0.06        **\<0.001**
  Lower Extremity function (SPPB) - points   0.81        **\<0.001**

*β*=Beta coefficient, CDAI=clinical disease activity index, VAS=visual analogue scale, CRP=C-reactive protein, IL-6=interleukin-6, TNF-alpha=tumor necrosis factor-alpha, s/b DMARD=synthetic/biological disease-modifying antirheumatic drug, RA=rheumatoid arthritis, and SPPB=short physical performance battery.

###### 

Associations between grip strength, knee extensor strength, lower extremity function, and workability (workability index single item, WAS).

                              Workability (WAS)                                                                                                   
  --------------------------- ------------------- ------- -------------- ------------- ------- -------------- ------------- ------- ------------- -------------
  I                           HGS/KES/SPPB^a^     0.06    0.25           **0.012**     0.17    0.39           **\<0.001**   0.33    0.57          **\<0.001**
  II^b^                       HGS/KES/SPPB^a^     0.31    0.49           **\<0.001**   0.33    0.52           **\<0.001**   0.39    0.50          **\<0.001**
                              Age - years                 -0.21          **0.024**             -0.14          0.132                 -0.19         **0.040**
  Gender (female)                                 0.39    **0.001**                    0.35    **0.001**                    0.05    0.520         
  Education (higher)                              0.17    0.064                        0.17    0.054                        0.14    0.118         
  III^c^                      HGS/KES/SPPB^a^     0.45    0.25           **0.039**     0.45    0.36           **0.001**     0.51    0.35          **\<0.001**
                              Age - years                 -0.15          0.107                 -0.09          0.319                 -0.14         0.132
  Gender (female)                                 0.24    **0.032**                    0.26    **0.006**                    0.06    0.469         
  Education (higher)                              0.06    0.471                        0.08    0.328                        0.06    0.505         
  Disease duration - months                       -0.13   0.189                        -0.74   0.391                        -0.06   0.511         
  sDMARD therapy                                  -0.07   0.457                        -0.10   0.239                        0.08    0.317         
  Comedication                                    -0.17   0.193                        -0.21   0.104                        -0.16   0.217         
  Comorbidity                                     0.06    0.651                        0.07    0.589                        0.05    0.710         
  Pain (VAS) - points                             -0.36   **\< 0.001**                 -0.34   **\< 0.001**                 -0.39   **\<0.001**   

Linear regression analysis. *β*=standardised beta coefficient, HGS=handgrip strength, KES=knee extensor strength, SPPB=short physical performance battery, and s/b DMARD=synthetic/biological disease-modifying antirheumatic drug.

^a^per kg HGS/KES; per point of the SPPB score; ^b^model II adjusted for sociodemographic variables *p*≤0.02 in univariate analysis; ^c^model adjusted for sociodemographic and clinical variables *p*≤ 0.2 in univariate analysis.

[^1]: Academic Editor: Bruce M. Rothschild
